Singapore, Oct. 29 -- Brain-computer interfaces (BCIs) are entering a new phase of technological development, moving beyond experimental demonstrations towards practical applications that could transf... Read More
Singapore, Oct. 29 -- PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide- based therapeutics and PDRadiopharma Inc., a wh... Read More
Singapore, Oct. 29 -- Japan-based Astellas Pharma Inc. has entered into an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE(R) candidate. Under the agreement, ... Read More
Singapore, Oct. 29 -- Jiahui International Hospital has launched Jiahui International Cell Therapy Centre (JICC), building on landmark CAR-T cases and multidisciplinary expertise to serve patients fro... Read More
Singapore, Oct. 29 -- American multinational pharmaceutical company Merck (Known as Merck Sharp & Dohme or MSD outside the United States and Canada) has announced that the Health Sciences Authority (H... Read More
Singapore, Oct. 29 -- M42 and the American University in Dubai (AUD) have signed a Memorandum of Understanding (MoU) to expand practical learning opportunities for biology and pre-medical students, st... Read More
Singapore, Oct. 28 -- US-based Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral IL-23R inhibitor programme, including lead asset HCXT-2001, from Hong Kong-based PepStar... Read More
Singapore, Oct. 28 -- CELSET INC., a Korean biotechnology company specialising in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, introducing a Korean botulinum toxin brand ... Read More
Singapore, Oct. 28 -- The Singapore Population Oral Health Symposium was recently organised by the National Dental Centre Singapore (NDCS), that saw a gathering of thought leaders, healthcare professi... Read More
Singapore, Oct. 28 -- Japan-based Otsuka Pharmaceutical has announced that Otsuka BioVentures, LLC (OBV), a corporate venture capital (CVC) firm has begun strategic equity investments. OBV will make ... Read More